ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
for Refractory Cancer
Drug: Nivolumab
Sites in Philadelphia, Pittsburgh +11 more locations
Sponsor: Immatics US, Inc.
Sex: All·Age: 18+
Code: NCT03686124·Phase 1, Phase 2·Recruiting·Listed Sep 2018